MAM
APRE icon

Meeder Asset Management’s Aprea Therapeutics APRE Stock Holding History

Meeder Asset Management’s Portfolio APRE Stock Details APRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-56
Closed -$39K – 2042
2020
Q1 		$39K Buy
+56
New +$41.1K ﹤0.01% 999

Other funds holding APRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Meeder Asset Management's APRE Position: Q2 2020 in Review

Meeder Asset Management sold out of Aprea Therapeutics (APRE) in Q2 2020, closing a stake of 56 shares — an estimated $39K sold.

Meeder Asset Management first reported a position in APRE in Q1 2020 and held it in 1 quarter. The position peaked at $39K in Q1 2020. 64 funds tracked by Wall St. Rank hold APRE as of Q2 2020.

  • Meeder Asset Management reported no remaining Aprea Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Meeder Asset Management sold 56 Aprea Therapeutics shares in Q2 2020, an estimated $39K.
  • Meeder Asset Management first reported a position in Aprea Therapeutics in Q1 2020 and held it in 1 quarter.
  • Meeder Asset Management's Aprea Therapeutics position peaked at $39K in Q1 2020.
  • 64 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q2 2020.

Based on Meeder Asset Management's 13F filing for Q2 2020, filed 11 Aug 2020.